A Study to Establish Proof-of-Biology for MK0646 in Breast Cancer
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Dalotuzumab will induce a decrease in the growth factor signature.
Following single dose of study drug infused over 60 - 120 minutes
United States: Food and Drug Administration